MedTrace Logo

Triamcinolone Assisted Anterior Vitrectomy

NCT01051648 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2010-01-18

No results posted yet for this study

Summary

Injecting Triamcinolone acetenoide for visualizing and removing vitreous from the anterior chamber.

Conditions

  • Vitrectomy
  • Cataract

Interventions

DRUG

Intra ocular injection of triamcinolone acetonide

In all patients triamcinolone acetonide was prepared by keeping the bottle vertical to allow sedimentation of crystals thus removing the vehicle. It was then injected into the anterior chamber (2 ml with concentration 20 mg/ml) just prior to anterior vitrectomy. The direction of the tip of the needle was kept away from the corneal endothelium to minimize endothelial toxicity. Triamcinolone was removed as quickly \& completely as possible after finishing anterior vitrectomy

Sponsors & Collaborators

  • AL-Nour Eye Hospital

    collaborator OTHER

  • Kasr El Aini Hospital

    collaborator OTHER

  • Cairo University

    lead OTHER

Principal Investigators

  • Mostafa A EL-Helw, M.D. · Cairo unuversity & EL-Nour eye hospital

  • Ahmed M Emarah, M.D. · Cairo university & EL-Nour eye hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
47 Years
Max Age
79 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-12-31
Primary Completion
2008-02-29
Completion
2008-06-30

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01051648 on ClinicalTrials.gov